Mark Iwicki | Chairman, President and CEO |
Mary Reumuth | CFO |
Todd Bazemore | COO |
Kim Brazzell | Chief Medical Officer |
Hongming Chen | Chief Scientific Officer |
Niranjan Kameswaran | SVP, Strategy |
Christopher Neyor | JPMorgan |
Andreas Argyrides | Wedbush Securities |
François Brisebois | Oppenheimer |
Biren Amin | Jefferies |
Yi Chen | H.C. Wainwright |
Good morning, and welcome to the Kala Pharmaceuticals Fourth Quarter and Full Year 2020 Financial Results Conference Call. At this time, all participants are in a listen-only mode.
Following management’s prepared remarks, a Q&A session will be held.
As a reminder, this call is being recorded. I would now like to turn the call over to Niranjan Kameswaran, Senior Vice President of Strategy for Kala Pharmaceuticals.